Tiagabine

Authors


Clinical Research II. Novo Nordisk A/S, Noro Nordisk Park, 2760 Malov, Denmark.

Abstract

Summary: Tiagabine (TGB), a specific γ-aminobutyric acid (GABA)-uptake inhibitor, is a potential new antiepileptic drug with a novel mechanism of action. In animal models of epilepsy as well as in a placebo-controlled trial in patients with complex partial seizures, TGB showed significant anticonvulsant effects. TGB was well tolerated by most patients.

Ancillary